Cargando…
AIDing cancer treatment: Reducing AID activity via HSP90 inhibition
The activation induced deaminase (AID) catalyses the two key events underlying humoral adaptive immunity: class switch recombination and somatic hypermutation of antibody genes in B lymphocytes. AID accomplishes this task by directly deaminating cytosines within the genomic immunoglobulin locus, the...
Autores principales: | Rebhandl, Stefan, Geisberger, Roland |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677455/ https://www.ncbi.nlm.nih.gov/pubmed/26151367 http://dx.doi.org/10.1002/eji.201545832 |
Ejemplares similares
-
AID/APOBEC deaminases and cancer
por: Rebhandl, Stefan, et al.
Publicado: (2015) -
Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia
por: Rebhandl, Stefan, et al.
Publicado: (2014) -
AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells
por: Huemer, Michael, et al.
Publicado: (2014) -
Diptoindonesin G, a new Hsp90 drug
por: Wickramaratne, Anushka, et al.
Publicado: (2022) -
Fumarate hydratase inhibition activates innate immunity via mitochondrial nucleic acid release
por: Li, Xiang, et al.
Publicado: (2023)